List of Excipients in Branded Drug ERLEADA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Products LP	ERLEADA	apalutamide	59676-600	CELLULOSE, MICROCRYSTALLINE
Janssen Products LP	ERLEADA	apalutamide	59676-600	CROSCARMELLOSE SODIUM
Janssen Products LP	ERLEADA	apalutamide	59676-600	FERRIC OXIDE YELLOW
Janssen Products LP	ERLEADA	apalutamide	59676-600	FERROSOFERRIC OXIDE

ERLEADA Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Erleada (apalutamide) is a high-value oral androgen-receptor inhibitor supplied as immediate-release film-coated tablets. Its excipient opportunity is concentrated in high-dose direct-compression technology, dissolution control, tablet-size reduction, coating performance, stability, and generic lifecycle development. The commercial value is strongest for suppliers and CDMOs that can support a 240 mg once-daily tablet while preserving bioequivalence, mechanical strength, manufacturability, and patient adherence.

Erleada's active ingredient is poorly water soluble, and the marketed product uses a conventional oral solid-dose platform rather than a visibly differentiated lipid, amorphous, multiparticulate, or modified-release system. That profile creates opportunities for formulation optimization, but it also limits the strength of standalone excipient exclusivity. The most defensible commercial positions are likely to come from proprietary drug-excipient performance, particle engineering, process controls, and clinical or bioequivalence data rather than from commodity excipient supply alone.

What is Erleada and how is it formulated?

Erleada is apalutamide, an androgen receptor inhibitor approved by the FDA for non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer in combination with androgen deprivation therapy. The standard adult dose is 240 mg orally once daily, taken with or without food.[1]

The product is available in 60 mg and 240 mg immediate-release film-coated tablets. Patients can receive four 60 mg tablets when the 240 mg tablet is unavailable. Tablets must be swallowed whole and should not be crushed, chewed, or split unless specifically supported by regulatory data.[1]

Erleada dosage-form profile

Attribute	Erleada profile
Active ingredient	Apalutamide
Drug class	Androgen receptor inhibitor
Dosage form	Immediate-release film-coated tablet
Strengths	60 mg and 240 mg
Standard dose	240 mg once daily
Administration	With or without food
Release profile	Immediate release
Primary market	Prostate cancer
Regulatory pathway	FDA NDA
Manufacturer	Janssen Biotech, Inc., part of Johnson & Johnson
Key formulation issue	High daily dose combined with limited water solubility

The 240 mg tablet reduces pill burden compared with four 60 mg tablets. That creates a commercial advantage in adherence-sensitive oncology markets, particularly for older patients receiving multiple medicines.

What excipients are used in Erleada tablets?

The U.S. prescribing information identifies a conventional tablet core containing microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. The film coating contains hypromellose, hydroxypropyl cellulose, titanium dioxide, talc, and colorant components.[1]

Excipient functions

Excipient	Primary function	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports direct compression and tablet strength
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and process consistency
Magnesium stearate	Lubricant	Reduces sticking and ejection force
Hypromellose	Film former	Supports coating integrity and appearance
Hydroxypropyl cellulose	Film-forming and binder function	Can improve coating flexibility and adhesion
Titanium dioxide	Opacifier and pigment	Controls appearance and light protection
Talc	Anti-tacking and coating aid	Improves coating-process performance
Colorants	Product identification	Supports strength differentiation and brand recognition

The formulation indicates a standard immediate-release manufacturing platform. The key technical challenge is not controlled release. It is achieving reproducible dissolution and adequate tablet performance from a high-dose, poorly soluble active pharmaceutical ingredient.

How important is apalutamide solubility to excipient selection?

Apalutamide has limited aqueous solubility, making dissolution performance a central development issue. The marketed label does not identify a complex solubilization system such as a lipid vehicle, cyclodextrin, or surfactant-rich self-emulsifying formulation.[1]

That creates several formulation priorities:

1. Maintain rapid disintegration despite high drug loading.
2. Control wetting and dispersion of apalutamide particles.
3. Avoid excessive lubricant levels that can slow dissolution.
4. Preserve tablet hardness during packaging and shipment.
5. Control particle-size distribution and polymorphic form.
6. Demonstrate comparable exposure under fed and fasted conditions.

A generic or follow-on developer should treat excipient selection as part of the bioequivalence strategy. A simple substitution of microcrystalline cellulose grade, disintegrant grade, or lubricant level can alter porosity, wetting, disintegration time, and dissolution.

Potential performance-enhancing excipient approaches

Potential development routes include:

• Silicified microcrystalline cellulose to improve flow and compactability.
• Co-processed excipients to reduce segregation in a high-dose blend.
• Alternative superdisintegrant grades to improve breakup without increasing tablet friability.
• Wetting agents at low concentrations to improve dissolution.
• Spray-dried or granulated apalutamide-excipient systems.
• Amorphous solid dispersions if crystalline drug dissolution proves limiting.
• Particle-size engineering combined with conventional direct compression.
• Film-coating systems with improved moisture and light protection.

These approaches may improve product performance, but a more complex formulation can increase regulatory burden. The commercial optimum is likely to be the simplest formulation that matches the reference product's dissolution and pharmacokinetic profile.

What excipient strategy best supports the 240 mg Erleada tablet?

The 240 mg tablet is the central commercial target because it matches the labeled once-daily dose and reduces pill burden. The excipient strategy should prioritize drug loading, tablet dimensions, mechanical strength, and reproducible immediate release.

Recommended development priorities

A practical development sequence is:

Priority	Development objective	Commercial reason
1	Establish apalutamide particle-size and solid-state control	Reduces dissolution variability
2	Screen high-functionality diluents	Supports a smaller, stronger tablet
3	Optimize superdisintegrant concentration	Balances fast disintegration and tablet robustness
4	Minimize lubricant impact	Protects dissolution performance
5	Compare direct compression and granulation	Identifies the lowest-cost robust process
6	Optimize coating weight gain	Controls appearance, protection, and manufacturing cost
7	Confirm stability under ICH conditions	Supports global registration
8	Link in vitro dissolution to bioequivalence	Reduces development and regulatory risk

The main opportunity for an excipient supplier is not simply to sell a standard diluent. It is to provide a validated formulation package with supporting data on flow, compaction, dissolution, stability, and scale-up.

What formulation patents protect Erleada?

Patent protection for Erleada can cover the apalutamide molecule, pharmaceutical compositions, crystalline forms, processes, therapeutic use, and dosage regimens. Excipient-specific protection is usually narrower than active-ingredient or method-of-use protection.

A formulation patent could protect:

• A defined apalutamide particle-size distribution.
• A specific polymorph or crystalline form.
• A composition containing apalutamide with defined excipient ratios.
• A dissolution profile within specified time limits.
• A granulation or compression process.
• A coating system that improves stability.
• A dosage form that reduces pill burden.
• A combination regimen with androgen deprivation therapy.

The commercial strength of a formulation patent depends on whether the claims require a clinically meaningful or technically difficult result. Claims limited to common excipients at broad concentration ranges are more vulnerable to design-around strategies. Claims tied to a specific solid form, dissolution profile, manufacturing process, or stability outcome are generally more defensible.

How strong is the Erleada formulation patent estate?

The strongest barriers are likely to arise from active-ingredient, solid-state, method-of-use, and regulatory exclusivity rights rather than from the disclosed conventional excipient system. A generic manufacturer may be able to use different grades of microcrystalline cellulose, croscarmellose sodium, or coating polymer while achieving comparable product performance.

Patent strength should be evaluated across four layers:

Layer	Relevance to Erleada	Design-around potential
Active compound	Protects apalutamide itself	Low before expiry
Solid form and particle engineering	Can affect dissolution and stability	Moderate
Tablet composition	Covers excipient combinations and ratios	Moderate to high
Method of use	Protects prostate-cancer treatment regimens	Depends on claim scope and jurisdiction

The Orange Book remains the controlling source for current U.S. listed patents and regulatory exclusivity associated with the approved product.[2] Patent and exclusivity status can change through pediatric extensions, delistings, litigation outcomes, or settlement agreements.

When does Erleada lose exclusivity?

Erleada was approved by the FDA in 2018. Its commercial exclusivity is governed by a combination of patent rights, regulatory exclusivity, and any later-issued or extended rights.[1,2]

The relevant entry pathways are:

• Abbreviated New Drug Application approval after applicable patents and exclusivities expire or are successfully challenged.
• Paragraph IV certification alleging that listed patents are invalid, unenforceable, or not infringed.
• Paragraph III certification accepting delayed approval until patent expiry.
• 505(b)(2) development for a materially different formulation, dosage form, or route of administration.
• Post-expiry generic entry using a conventional immediate-release tablet.

The 240 mg strength can be strategically important. A developer that offers only four 60 mg tablets may face a commercial disadvantage even if it obtains approval. A 240 mg product better matches the reference product's dosing convenience and pharmacy substitution expectations.

Which companies are challenging Erleada patents?

Public patent challenges should be tracked through FDA ANDA records, Paragraph IV litigation filings, and federal district court dockets. The leading potential challengers are generic companies with oncology portfolios and tablet-manufacturing capabilities, including large U.S. and international generic manufacturers.

The commercial assessment should focus on:

• First-filer status.
• ANDA filing date.
• Paragraph IV notice date.
• The patents challenged.
• Whether the patent holder filed suit within the statutory period.
• The availability of 180-day exclusivity.
• Settlement terms and permitted launch dates.
• Whether the challenger has a 240 mg tablet or only a 60 mg equivalent.

A Paragraph IV filing can create value even before launch because it may establish first-filer rights, create settlement leverage, or accelerate licensing discussions. Litigation outcomes can materially change the competitive timing of generic apalutamide.

What is the Orange Book status of Erleada?

Erleada is an FDA-approved small-molecule drug listed under an NDA rather than a biologic license application. It is therefore subject to the small-molecule patent-listing and ANDA framework reflected in the Orange Book.[2]

Orange Book analysis should separate:

1. FDA regulatory exclusivity.
2. Listed drug patents.
3. Method-of-use patent claims.
4. Composition or formulation claims.
5. Patent expiration and pediatric-extension dates.
6. Litigation-triggered approval stays.
7. Settlement-based launch restrictions.

The absence of a complex biologic manufacturing platform reduces biosimilar risk. Erleada faces generic, not biosimilar, competition. That distinction matters because an ANDA sponsor can generally rely on the reference product's safety and efficacy findings while demonstrating pharmaceutical equivalence and bioequivalence.

What generic entry risks exist for Erleada?

Generic entry risk is material because Erleada is an oral small molecule with a conventional tablet dosage form. The principal barriers are patent timing, apalutamide dissolution, solid-state control, and oncology-market access rather than complex administration technology.

Generic launch scenarios

Scenario	Market effect
No early Paragraph IV challenge	Delayed competition until relevant rights expire
Successful Paragraph IV challenge	Potential early launch, subject to litigation and exclusivity
Settlement with licensed entry	Predictable but potentially delayed generic competition
One 240 mg generic entrant	Initial price pressure with limited breadth
Multiple generic entrants	Rapid reimbursement and net-price erosion
60 mg-only generic competition	Partial substitution but weaker adherence proposition
240 mg and 60 mg competition	Broad substitution across prescriptions

The high value of prostate-cancer treatment creates an attractive target for generic manufacturers. However, payer conversion may depend on pharmacy substitution rules, formulary placement, physician familiarity, and availability of the 240 mg strength.

What commercial opportunities exist for excipient suppliers?

The most attractive opportunities fall into five categories.

High-performance direct-compression excipients

Suppliers can position premium microcrystalline cellulose, silicified cellulose, co-processed diluents, and high-efficiency disintegrants for high-dose apalutamide tablets. The value proposition should emphasize lower tablet weight, improved tensile strength, better flow, and consistent dissolution.

Solubility and dissolution technologies

A supplier with a validated wetting, dispersion, amorphous, or particle-engineering platform may offer a differentiated solution. The technology must preserve stability and demonstrate a clear performance advantage over conventional excipients.

Film-coating systems

Coating suppliers can compete through low-weight-gain coatings, improved adhesion, reduced defects, moisture protection, and color consistency across the 60 mg and 240 mg strengths.

Generic formulation packages

An excipient company or CDMO can offer an integrated platform covering formulation screening, process development, analytical methods, scale-up, and bioequivalence support. This approach is more commercially defensible than selling individual commodity ingredients.

Global supply and regulatory support

A dual-source excipient strategy can reduce supply-chain risk. Suppliers with Drug Master Files, strong change-control systems, compendial compliance, and global regulatory support have an advantage in multi-jurisdictional generic development.

How does Erleada compare with competing androgen-receptor inhibitors?

Product	Active ingredient	Dosage form	Excipient opportunity
Erleada	Apalutamide	Immediate-release tablet	High-dose compression and dissolution
Xtandi	Enzalutamide	Capsule and tablet presentations	Solubility, capsule/tablet transition, dose burden
Nubeqa	Darolutamide	Film-coated tablet	Conventional tablet optimization
Zytiga	Abiraterone acetate	Tablet	High-dose tablet and food-effect management

Erleada's 240 mg daily dose creates a stronger pill-burden incentive than some competing products. Its immediate-release tablet platform also makes generic substitution technically more accessible than a complex injectable or biologic product.

What manufacturing and intellectual-property barriers affect Erleada?

Manufacturing barriers include apalutamide powder handling, blend uniformity, dissolution reproducibility, tablet-size constraints, coating defects, and stability under humidity and light exposure. Intellectual-property barriers may include active-compound claims, solid forms, pharmaceutical compositions, therapeutic uses, and manufacturing processes.

A robust commercial development program should control:

• Apalutamide polymorph and particle-size distribution.
• Blend segregation during high-dose processing.
• Lubrication time and magnesium stearate distribution.
• Compression force and tablet tensile strength.
• Disintegration after coating.
• Dissolution across pH conditions.
• Packaging moisture protection.
• Stability after process and excipient changes.

These parameters can support both regulatory approval and patentable manufacturing or composition claims.

What revenue exposure does Erleada create?

Erleada is a major oncology product for Johnson & Johnson, with reported annual sales in the billion-dollar range in recent company filings.[3] Generic entry would expose the product to the standard small-molecule erosion pattern: an initial decline after the first approved generic, followed by steeper price and volume pressure as additional suppliers enter.

Revenue exposure depends on:

• Timing of the first generic launch.
• Number of approved manufacturers.
• Whether a 240 mg generic is available.
• Payer and specialty-pharmacy substitution.
• Continued growth in metastatic castration-sensitive prostate cancer.
• Physician use of competing androgen-receptor inhibitors.
• Any authorized generic or licensing arrangement.

The highest-value commercial positions are therefore early generic entry, first-filer rights, authorized-generic supply, and differentiated excipient or CDMO partnerships that reduce development time.

Key Takeaways

• Erleada is a high-dose, immediate-release apalutamide tablet using conventional excipients.
• The core formulation uses microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate, with a polymeric film coating.[1]
• The strongest excipient opportunities involve dissolution, compactability, tablet-size reduction, coating performance, and process robustness.
• The 240 mg tablet is commercially more important than a 60 mg-only presentation because it matches the standard once-daily dose.
• Erleada is exposed to generic competition rather than biosimilar competition.
• Standalone excipient patents are likely to be less valuable than patents tied to solid form, particle engineering, dissolution, stability, or manufacturing.
• Generic entry timing depends on Orange Book patents, Paragraph IV litigation, settlement terms, and first-filer status.
• Premium excipient suppliers should offer formulation and regulatory support rather than commodity ingredients alone.
• Johnson & Johnson's billion-dollar-scale Erleada revenue creates meaningful exposure to successful early generic entry.[3]

FAQs

Can Erleada tablets be reformulated with different excipients?

Yes. A generic manufacturer can generally use different inactive ingredients if the product meets applicable pharmaceutical-equivalence, bioequivalence, quality, and labeling requirements. Excipients that alter dissolution or absorption require particular scrutiny.

Is Erleada a controlled-release formulation?

No. Erleada is an immediate-release film-coated tablet. Its formulation challenge is primarily dissolution and high-dose tablet performance rather than extended-release control.

Is there a commercial opportunity for an Erleada liquid formulation?

Potentially, but a liquid would require new formulation, stability, dosing, palatability, packaging, and regulatory work. The strongest initial opportunity remains the 240 mg immediate-release tablet because it aligns with the approved dosing regimen.

Can an excipient supplier obtain patent protection for an apalutamide formulation?

Potentially. Protection is more credible when the formulation includes a defined solid form, particle-size range, dissolution result, stability benefit, or manufacturing process rather than only a broad list of conventional excipients.

Does Erleada require biosimilar development?

No. Apalutamide is a small-molecule active ingredient, so competing products would generally pursue the generic drug pathway through an ANDA rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). Erleada (apalutamide) prescribing information. Janssen Biotech, Inc.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

3. Johnson & Johnson. (2025). 2024 annual report. Johnson & Johnson.